CPRX Catalyst Pharmaceuticals Inc.

+0.88  (+22%)
Previous Close 4.02
Open 4.05
Price To Book 10.01
Market Cap 503720303
Shares 102,739,257
Volume 7,411,199
Short Ratio
Av. Daily Volume 1,091,281

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 1H 2020.
Spinal Muscular Atrophy (SMA) Type 3
Phase 3 data due 2H 2019.
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 data due 2H 2019.
Congenital Myasthenic Syndromes (CMS)
FDA approval announced November 28, 2018.
Lambert-Easton Myasthenic Syndrome (LEMS)

Latest News

  1. 2 High-Growth Stocks I'd Buy Right Now
  2. Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT
  3. Why Catalyst Pharmaceuticals Stock Is Popping Today
  4. Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
  5. The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed
  6. Catalyst: 4Q Earnings Snapshot
  7. Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  8. The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Has Gained 181%, So Why Not Pay It Some Attention?
  9. Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
  10. U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug
  11. Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
  12. Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome
  13. Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
  14. Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
  15. Catalyst Pharma sees net price of drug, once free, topping $300,000
  16. Coral Gables company under fire for drug pricing says patient care is 'top priority'
  17. Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference
  18. U.S. Senator Sanders asks why drug, once free, now costs $375k
  19. What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?